Androgen receptor status is highly conserved during tumor progression of breast cancer.

摘要: With the advent of new and more efficient anti-androgen drugs targeting androgen receptor (AR) in breast cancer (BC) is becoming an increasingly important area investigation. This would potentially be most useful triple negative BC (TNBC), where better therapies are still needed. The assessment AR status generally performed on primary tumor even if has already metastasized. Very little known regarding discrepancies during progression. To determine prevalence positivity, with emphasis TNBCs, to investigate progression, we evaluated a large series BCs matching metastases recurrences. was 356 BCs, 135 metastases, 12 recurrences using next-generation Tissue Microarray (ngTMA). A commercially available antibody used AR-status by immunohistochemistry. positivity defined as any nuclear staining cells ≥1 %. expression correlated pathological features tumor. Additionally, concordance rate between different sites determined. positive in: 87 % (307/353) tumors, 86.1 (105/122) 66.7 (8/12) TNBC tested 11.4 %, (4/35) BCs. discrepant result seen 4.3 (5/117) lymph node (LN) metastases. Three were LN metastasis, representing 17.6 all (3/17). Two 2.0 (2/100). No distant or recurrence (n = 17). Most (87 %) metastasized (86.1 including significant fraction TNBCs (11.4 %). Further, highly conserved progression change only occurs small (4.1 Our study supports notion that could effective for many patients re-testing formerly mixed type BC’s recommended.